证券代码：300878 证券简称：维康药业 公告编号：2025-031 浙江维康药业股份有限公司 第四届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 （二）审议通过《关于 2025 年半年度募集资金存放与使用情况的专项报告 的议案》 经审议，董事会通过了公司《2025 年半年度募集资金存放与使用情况的专 项报告》。具体内容详见公司同日在巨潮资讯网（http://www.cninfo.com.cn）披 露的相关公告。 表决结果：同意：7 票；反对：0 票；弃权：0 票。 （三）审议通过《关于部分募集资金投资项目延期的议案》 经审议，董事会认为公司根据募集资金投资项目的实际建设情况和投资进 度，采取审慎的态度调整募集资金投资项目"营销网络中心建设项目"达到预定 可使用状态的日期，符合募集资金投资项目的实际情况和公司的发展规划，不存 在改变或变相改变募集资金投向和其他损害股东利益的情形，同意公司将上述募 集资金投资项目达到预定可使用状态的日期延长至 2026 年 6 月 30 日。 表决结果：同意：7 票；反对：0 ...

浙江维康药业股份有限公司 2025 年半年度报告全文 证券代码：300878 证券简称：维康药业 公告编号：2025-034 浙江维康药业股份有限公司 2025 年半年度报告 2025 年 8 月 1 浙江维康药业股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人刘洋、主管会计工作负责人王静及会计机构负责人(会计主管 人员)王静声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成本公司 对任何投资者及相关人士的承诺，投资者及相关人士均应对此保持足够的风 险认识，并且应当理解计划、预测与承诺之间的差异，敬请广大投资者注意 投资风险。 公司在经营中可能存在的风险因素内容已在本报告"第三节 管理层讨论 与分析"之"十、公司面临的风险和应对措施"部分予以描述，敬请投资者 注意并仔细阅读该章节全部内容。 浙江维康药业股份有限公司 ...

Core Viewpoint - The article emphasizes the importance of small and medium-sized enterprises (SMEs) in China's economy, highlighting their role in driving innovation and sustaining industrial upgrades in the context of rapid technological advancements and global economic changes [1]. Group 1: Importance of SMEs - SMEs are crucial for improving industrial structure and unleashing innovation in China, serving as a vital force for the country's new productive forces [1]. - The "NEXT20" initiative aims to systematically research and track the growth potential of small-cap listed companies in the capital market, addressing the gap in growth research and evaluation for these firms [1]. Group 2: Evaluation Process - The evaluation team has initiated on-site visits to several shortlisted companies, including those in the semiconductor and power equipment sectors, as well as advanced medical device firms with high R&D capabilities [2]. - The evaluation process involves multiple rigorous assessment stages, including data screening, quantitative scoring, and voting by judges, ultimately selecting 68 companies for further research [1][2]. Group 3: Insights from Companies - During discussions, company managers shared key milestones in their development and showcased the core drivers of their growth and technological innovation [3]. - Companies demonstrated a strong understanding of future trends and exhibited confidence in their product's market appeal and customer retention [3]. Group 4: Global Expansion Strategies - Many tech innovation companies view international expansion as a key strategy for market growth, with firms showing rational consideration of risks and returns in overseas markets [5]. - Companies expressed confidence in their technological capabilities and clarity in their future growth objectives [5]. Group 5: Future Plans - The evaluation team plans to continue in-depth assessments of shortlisted companies across various cities, including Beijing, Qingdao, Hangzhou, and Taizhou, to evaluate their comprehensive strength and industry advantages [9]. - The "NEXT20" list will be unveiled in November, accompanied by a forum and award ceremony in Shanghai, bringing together government leaders, experts, and industry representatives to discuss the cultivation of new productive forces [9].

Group 1 - The stock price of Weikang Pharmaceutical as of August 18, 2025, is 25.24 yuan, down 0.86% from the previous trading day [1] - The stock exhibited volatility, opening at 25.25 yuan, reaching a high of 26.00 yuan, and a low of 24.59 yuan, with an amplitude of 5.54% [1] - There was a rapid rebound in the stock price, with a more than 2% increase within 5 minutes at 9:35 AM, and a transaction amount of 25.85 million yuan [1] Group 2 - Weikang Pharmaceutical focuses on pharmaceutical manufacturing, with main business activities including the research, production, and sales of traditional Chinese medicine and chemical drugs [1] - The company's products cover multiple therapeutic areas, including medications for respiratory and digestive system diseases [1] Group 3 - The net outflow of main funds for Weikang Pharmaceutical on that day was 18.22 million yuan, with a cumulative net outflow of 21.31 million yuan over the past five days [1] - The turnover rate for the day was 6.92%, with a trading volume of 99,688 hands and a total transaction amount of 252 million yuan [1]

证券之星消息，8月12日中药板块较上一交易日下跌0.41%，维康药业领跌。当日上证指数报收于 3665.92，上涨0.5%。深证成指报收于11351.63，上涨0.53%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 002287 | 奇正藏药 | 29.67 | 2.49% | 23.50万 | | 7.01亿 | | 600572 | 康恩贝 | 4.71 | 1.95% | 96.59万 | | 4.62亿 | | 300147 | ST香雪 | 7.77 | 1.17% | 11.73万 | | 9168.28万 | | 600557 | 康缘药业 | 17.65 | 1.09% | 24.87万 | | 4.44亿 | | 002275 | 桂林三金 | 15.68 | 0.90% | 12.34万 | | 1.94亿 | | 002728 | 特一药业 | 9.47 | 0.74% | 28.22万 | | 2.68亿 | | 300026 ...

Group 1 - The core point of the article is the resignation of Zhu Ting from the position of Secretary of the Board at Weikang Pharmaceutical due to personal reasons, while she will continue to serve as a director [2] - Zhu Ting's original term as Secretary of the Board was set to last until May 19, 2027 [2] - To ensure the continuity of information disclosure and related duties, the Chairman Liu Yang will temporarily assume the responsibilities of the Secretary of the Board until a new appointment is made [2]

维康药业（SZ 300878，收盘价：23.72元）8月8日晚间发布公告称，浙江维康药业股份有限公司董事会 于2025年8月8日收到公司董事会秘书、董事朱婷女士提交的书面辞职报告。朱婷女士因个人原因，申请 辞去公司董事会秘书职务。朱婷女士将继续在公司担任董事一职。 2024年1至12月份，维康药业的营业收入构成为：医药制造占比57.79%，医药批发零售占比41.01%，其 他业务占比1.19%。 （文章来源：每日经济新闻） ...

Group 1 - The company announced on August 8 that it received a written resignation report from its board secretary and director, Zhu Ting, who is resigning for personal reasons [1] - Zhu Ting's resignation as board secretary is effective immediately upon delivery of the resignation report to the board [1] - After resigning from the board secretary position, Zhu Ting will continue to serve as a director of the company [1] Group 2 - To ensure the normal operation of information disclosure and other duties, the company's chairman, Liu Yang, will temporarily act as the board secretary until a new board secretary is appointed [1]

证券代码：300878 证券简称：维康药业 公告编号：2025-030 朱婷女士辞任董事会秘书职务不会影响公司正常运作，公司将按照《深圳证 券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号 ——创业板上市公司规范运作》等有关法律法规、规范性文件及《公司章程》的 规定，尽快确定董事会秘书候选人并完成董事会秘书的聘任工作。 为保证公司信息披露等工作正常进行，在新任董事会秘书到任前，暂由公司 董事长刘洋先生代行董事会秘书职责。 公司董事长刘洋先生代行董事会秘书职责期间的联系方式如下： 电话：0578-2950005 浙江维康药业股份有限公司 关于公司董事会秘书辞职暨董事长代行董事会 秘书职责的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、关于董事会秘书辞职的情况 浙江维康药业股份有限公司（以下简称"公司"）董事会于 2025 年 8 月 8 日收到公司董事会秘书、董事朱婷女士提交的书面辞职报告。朱婷女士因个人原 因，申请辞去公司董事会秘书职务。根据《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作》和《公 ...

Core Viewpoint - The article highlights serious financial misconduct at Weikang Pharmaceutical, including the misuse of company funds by its actual controller, Liu Zhongliang, and the subsequent impact on the company's financial performance and project timelines [3][4][6]. Financial Misconduct - Liu Zhongliang has occupied company funds totaling 157 million yuan, including 54 million yuan of raised funds, under the guise of paying for engineering equipment [1][4]. - The funds were ultimately transferred to personal accounts controlled by Liu Zhongliang, constituting non-operational fund occupation [3][4]. - The balances of fund occupation by the actual controller from 2020 to mid-2023 were 78.12 million yuan, 89.51 million yuan, 147.28 million yuan, and 151.22 million yuan, representing 5.64%, 6.35%, 10.43%, and 10.24% of net assets respectively [3][4]. Regulatory Actions - The Zhejiang Securities Regulatory Bureau has ordered Weikang Pharmaceutical to rectify the situation, issuing a warning and imposing a fine of 5 million yuan on the company and 7 million yuan on Liu Zhongliang [4][6]. Project Delays - Weikang Pharmaceutical's initial fundraising projects have faced multiple delays, with the first phase of the health industry park originally scheduled for completion in December 2020, now pushed back multiple times to 2025 [6][7]. - The marketing center project has also seen significant delays, with no new investments reported for 2023 and 2024 [7][8]. Financial Performance - The company's financial performance has deteriorated significantly since its IPO, with net profit dropping from 96 million yuan in 2021 to a loss of 147 million yuan in 2024 [9][10]. - Revenue has also declined from 633 million yuan in 2021 to 351 million yuan in 2024, contrasting sharply with pre-IPO growth [9][10]. Dividend Payments - Despite the losses, Weikang Pharmaceutical has continued to distribute dividends, with cash dividends of 35.51 million yuan in 2023 and 19.89 million yuan in 2024, even as the actual controller holds nearly 70% of the company's shares [11].